Why the study?
Angiosarcoma is a rare malignancy lacking treatment consensus, and the role, efficacy, and timing of chemotherapy remain uncertain.
Does weekly doxorubicin, paclitaxel, and cisplatin improve outcomes in patients with angiosarcoma?
Comparison
Weekly doxorubicin, paclitaxel, and cisplatin followed by radiation or surgical resection
Design
Case descriptions
Authors
Loading...
May support chemotherapy in select angiosarcoma cases; leaves open need for RCTs to define role and timing.
Does weekly doxorubicin, paclitaxel, and cisplatin improve outcomes in patients with angiosarcoma?
A combination of doxorubicin, paclitaxel, and cisplatin may be an effective neoadjuvant or alternative treatment for angiosarcoma.
Lewcun et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: